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PLINICAL RESEARCH Clinical Trials
omparative Effects of Antiplatelet,
nticoagulant, or Combined Therapy in Patients
ith Valvular and Nonvalvular Atrial Fibrillation
Randomized Multicenter Study
rancisco Pérez-Gómez, PHD, FESC,* Eduardo Alegrı´a, MD, PHD,† Jesus Berjón, MD, PHD,‡
ose A. Iriarte, MD, PHD,§ Javier Zumalde, MD, Antonio Salvador, MD, PHD,¶
uis Mataix, MD,# for the NASPEAF Investigators
adrid, Pamplona, Bilbao, and Valencia, Spain
OBJECTIVES This trial evaluated the efficacy and safety of the combination of antiplatelet and moderate-
intensity anticoagulation therapy in patients with atrial fibrillation associated with recognized
risk factors or mitral stenosis.
BACKGROUND Warfarin was more effective than aspirin in preventing stroke in these patients; combined
therapy with low anticoagulant intensity was ineffective. Mitral stenosis patients were not
investigated.
METHODS We performed a multicenter randomized trial in 1,209 patients at risk. The intermediate-risk
group included patients with risk factors or age 60 years: 242 received the cyclooxygenase
inhibitor triflusal, 237 received acenocumarol, and 235 received a combination of both. The
high-risk group included patients with prior embolism or mitral stenosis: 259 received
anticoagulants and 236 received the combined therapy. Median follow-up was 2.76 years.
Primary outcome was a composite of vascular death and nonfatal stroke or systemic embolism.
RESULTS Primary outcome was lower in the combined therapy than in the anticoagulant arm in both
the intermediate- (hazard ratio [HR] 0.33 [95% confidence interval (CI) 0.12 to 0.91]; p 
0.02) and the high-risk group (HR 0.51 [95% CI 0.27 to 0.96]; p  0.03). Primary outcome
plus severe bleeding was lower with combined therapy in the intermediate-risk group.
Nonvalvular and mitral stenosis patients had similar embolic event rates during anticoagulant
therapy.
CONCLUSIONS The combined antiplatelet plus moderate-intensity anticoagulation therapy significantly
decreased the vascular events compared with anticoagulation alone and proved to be safe in
atrial fibrillation patients. (J Am Coll Cardiol 2004;44:1557–66) © 2004 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.05.084College of Cardiology Foundation
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rtrial fibrillation (AF) is the most prevalent cardiac ar-
hythmia and is also a strong independent risk factor for
oth systemic embolism and stroke (1,2). Since 1989,
everal randomized studies on stroke prevention (3) have
ested two antithrombotic agents: warfarin and aspirin.
See page 1567
ome meta-analyses (4–6) showed that warfarin decreases
troke by 62% compared with placebo. In studies where a
tatistical benefit with aspirin has been shown, this benefit is
uch less than seen with warfarin, with fewer bleeding
omplications and easier monitoring (4). In order to reduce
From the *Hospital Clı´nico San Carlos, Madrid, Spain; †Clı´nica Universitaria de
avarra, Pamplona, Spain; ‡Hospital de Navarra, Pamplona, Spain; §Hospital de
asurto, Bilbao, Spain; Hospital Galdakao, Bilbao, Spain; ¶Hospital Dr. Peset,
alencia, Spain; and #Centro Especialidades Avenida de Portugal, Madrid, Spain.
he secretariat, data bank, statistical analysis, and expenses for working meetings were
upported by grants from the Spanish Society of Cardiology (Madrid) and Uriach
oundation (Barcelona).(
Manuscript received February 18, 2004; revised manuscript received May 3, 2004,
ccepted May 11, 2004.oth thromboembolic and bleeding events, the combination
f low-dose warfarin and aspirin was investigated in three
rials (7–9). All concluded that this combination therapy
ith an international normalized ratio (INR) below 1.5 was
neffective.
Theoretically, the combination of therapeutic doses of
nticoagulant and antiplatelet agents (i.e., combined ther-
py) should have additional benefits and, recently, the
arfarin Aspirin Re-Infarction Study (WARIS) II found it
uperior to aspirin alone in the prevention of vascular events
fter myocardial infarction (MI) (10). Our trial has evalu-
ted, for the first time, the efficacy and safety of this
ombination compared with one antiplatelet or anticoagu-
ation alone in nonvalvular AF and in patients with mitral
tenosis.
ATIENTS AND METHODS
ligible patients. Patients with chronic or documented
aroxysmal AF were eligible for the study. Patients at low
isk according to Stroke Prevention in Atrial Fibrillation
SPAF) III stratification (7) or younger than 60 years of age
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roups: the high-risk group included nonvalvular plus prior
mbolism and patients with mitral stenosis with and with-
ut prior embolism. All others were included in the
ntermediate-risk group. Exclusion criteria were mechanical
alve prosthesis, stroke in the previous six months, serum
reatinine over 3 mg/dl, alcoholism or drug addiction,
evere uncontrolled hypertension, diffuse arteriosclerosis,
nd indication for non-steroidal anti-inflammatory drugs or
ndication/contraindication for antiplatelet or anticoagulant
herapy.
tudy design and organization. The National Study for
revention of Embolism in Atrial Fibrillation (NASPEAF)
s a prospective, multicenter, randomized open-label study.
hirteen Spanish hospitals participated according to the
rinciples of the Helsinki Declaration. The ethical commit-
ee of each institution approved the protocol and the
atient’s written informed consent was signed. Two blind
vents and safety committees, composed of members not
nvolved in the running of the trial, validated all events and
onitored the safety of treatments. The core center for data
ollection and statistical analysis was San Carlos University
ospital in Madrid. The Working Group on Thrombosis
f the Spanish Cardiac Society had access to the database
hroughout the study.
The antiplatelet agent used was triflusal (Grupo Uriach,
pain), a drug structurally related to acetylsalicylic acid (11),
f which clinical trials showed that 600 mg/day has similar
iologic effects and clinical efficacy to aspirin 300 mg/day
ith fewer bleeding complications (12,13). The anticoagu-
ant used was acenocoumarol (Novartis Farmaceutica,
pain), the coumarin derivative most used in several Euro-
ean countries.
Randomization was balanced, computer-generated, and
dministered centrally. It was also balanced by study center
nd by the three high-risk subgroups. The randomization
equence could not be previewed. Patients in the
ntermediate-risk group were randomized to one of the
hree arms: oral anticoagulation to a target INR of 2 to 3,
riflusal 600 mg daily, or a combination of both with a target
NR of 1.25 to 2. In the high-risk group, the triflusal-only
Abbreviations and Acronyms
AF  atrial fibrillation
AFASAK  Copenhagen Study on Atrial Fibrillation
CI  confidence interval
EAFT  European Atrial Fibrillation Trial
HR  hazard ratio
INR  international normalized ratio
MI  myocardial infarction
NASPEAF  National Study for Prevention of
Embolism in Atrial Fibrillation
SPAF  Stroke Prevention in Atrial Fibrillation
TIA  transient ischemic attack
WARIS  Warfarin Aspirin Re-Infarction Studyrm was omitted and subjects were assigned to anticoagu- fation with a target INR of 2 to 3 or the combination
herapy with a target INR of 1.4 to 2.4.
Demographic data, risk factors, concomitant heart dis-
ase, blood pressure, clinical examination, electrocardio-
ram, and echocardiogram were recorded at baseline. Clin-
cal follow-up was scheduled every six months for a
aximum of four years. In between, the patients were under
he care of their general practitioners. Follow-up was
nterrupted after a primary outcome or a prosthetic valve
mplantation. Any possible way (hospital records, phone
alls) was used to detect any new event in cases lost to
ollow-up. This information was registered in a final form.
nticoagulation was controlled at specialized units by re-
ording mean treatment dose, mean INR, time within the
reset range, number of INR controls out of the preset
ange, number of INR controls 3.5 and 2, and the
ntercontrol intervals.
utcome events. Primary outcome was a composite of
ascular death, transient ischemic attack (TIA), and nonfa-
al stroke or systemic embolism, whichever came first. We
lso prospectively registered as secondary events severe
leeding, MI, nonvascular death, and non-severe bleeding.
hese outcomes alone or in combination were also
nalyzed. The composite of primary outcomes and severe
leeding was jointly analyzed to evaluate the benefit-to-
isk ratio.
Stroke and TIA were defined as focal neurologic deficits
asting24 h or24 h, respectively. Neuroimaging defined
he ischemic or intracranial hemorrhagic etiology. Systemic
mbolism was diagnosed after an abrupt vascular insuffi-
iency without previous clinical symptoms. Vascular death
ncluded either sudden or any other death occurring within
0 days after a vascular event or progressive heart failure.
leeding was considered severe when requiring hospital
dmission, blood transfusion, or surgery (14).
tatistics. For sample size calculation in the intermediate-
isk group, we used the aspirin and anticoagulation arms
vents rate of the SPAF II younger group (15) and Copen-
agen Study on Atrial Fibrillation (AFASAK) I (3) trials.
he composite of nonfatal stroke, TIA, systemic embolism,
nd vascular death in the aspirin arm was 4.72 per 100
erson-years in the SPAF II study and 4.8 in the AFASAK
trial. The rates in the anticoagulation arm were 3.53 and
.2, respectively. The anticoagulation arm event rate in the
igh-risk group was based on the European Atrial Fibrilla-
ion Trial (EAFT) (16), where the primary event rate was
.0. There were no published trials to assume event rate in
he combined arms, because the anticoagulation intensity
sed resulted subtherapeutic, but Turpie et al. (17), using
igh anticoagulation intensity associated with aspirin 100
g/day for embolic prevention in patients with prosthetic
eart valves, showed a benefit of 61%. We hypothesized
hat, using a moderate level of anticoagulation in our
ombined arms, a 40% reduction in the event rate should be
linically relevant. Assuming these figures, in a four-year
ollow-up period, two-tailed alpha-error of 0.05, and a
p
t
r
t
f
t
a
i
r
a
f
m
l
t
c
p
r
o
s
i
c
c
d
b
r
M
o
t
u
a
e
t
S
S
R
R
2
p
t
f
(
t
w
p
a
a
b
P
i
i
c
H
e
c
F

1559JACC Vol. 44, No. 8, 2004 Pérez-Gómez et al.
October 19, 2004:1557–66 Antithrombotic Therapy in Atrial Fibrillationower of 80%, the calculated cohort was 813 for each
reatment arm of the intermediate- and 197 for the high-
isk group.
The safety committee decided to review outcomes after
he SPAF III study reported in September 1996 (7) the
ailure of the combined therapy arm. This therapy in our
rial presented no greater number of events than the other
rms, and the median INR in the combined arms of both
ntermediate- and high-risk groups was 1.93 and 2.08,
espectively. A similar level of INR was maintained
fterward. In February 2000, when the calculated sample
or the high-risk group was complete, the events com-
ittee analyzed the outcomes, which were significantly
ower in the combined arm. The committee then decided
o also analyze the intermediate-risk group, and the
ombined therapy also showed a significant benefit com-
ared with other arms. Therefore, it was decided to finish
ecruitment in this group and continue the follow-up for
ne more year of cases that had not completed the
cheduled follow-up period.
Statistical analyses were performed according to the
ntention-to-treat and “on-treatment” principles. Baseline
omparisons were performed using the chi-square test for
ategorical data and analysis of variance test for continuous
ata. A logistic multivariate analysis was made to adjust
aseline comparisons. The incidences were expressed as
ates (events per 100 person-years). We used the Kaplan-
eier method to calculate the four-year cumulative rate of
utcome events until the first event occurred. The represen-
igure 1. Flow diagram of the NASPEAF. Lost to follow-up corresponds
international normalized ratio; ITT  intention to treat; IQR  interation of these charts was cut at the median follow-up. We csed the hazard ratio (HR), 95% confidence interval (CI) of
Cox regression model, and the log-rank statistics to
xpress the efficacy and safety of the different treatments. All
ests were carried out at a 0.05 level of significance.
tatistical analysis was performed using SPSS (Version 8.0,
PSS Inc., Chicago, Illinois).
ESULTS
ecruitment started in June 1995 and stopped in February
000. The study was closed in June 2001. The number of
atients recruited was 1,209. Figure 1 shows their distribu-
ion: 714 entered the intermediate-risk group (median
ollow-up 965 days) and 495 entered the high-risk group
median follow-up 1,075 days). The following reasons for
reatment withdrawals were registered: adverse events (9%),
ithout significant difference among groups; and general
ractitioner’s or patient’s decision (9.3%). These withdraw-
ls resulted in a change from the combined treatment to the
nticoagulant alone in 56 patients. The treatment arms were
alanced with respect to baseline characteristics (Table 1).
atients with prior embolism at baseline presented a signif-
cantly higher rate of female gender, hypertension, diabetes,
schemic heart disease, hyperlipidemia, and peripheral vas-
ular disease; had a larger left atrium; and were older.
owever, multivariate analysis showed significant differ-
nces only for the last four of these factors.
Table 2 shows the anticoagulation control data. The
ombined therapy had a lower median INR than the
se patients about whom no data about efficacy and safety is available. INR
le range.to tho
quartiorresponding anticoagulant arms (1.93 vs. 2.47 and 2.17 vs.
2
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Antithrombotic Therapy in Atrial Fibrillation October 19, 2004:1557–66.50 in the intermediate- and high-risk groups, respec-
ively). The combined arms also had a higher number of
NR controls2 in either risk group (67% vs. 21% and 39%
s. 18%) and a lower number of INR controls 3.5 (1.96%
s. 6.30% and 2.40% vs. 7.90%) (p  0.001 for all).
utcomes. Primary events in the intermediate-risk group
ere recorded in 42 cases (Table 3). Figure 2A shows the
vent-free survival curves and Figure 3 shows the HR. The
ombined therapy arm presented fewer primary events than
he antiplatelet (HR 0.24 [95% CI 0.09 to 0.64]; p 0.001)
r the anticoagulant-alone group (HR 0.33 [95% CI 0.12 to
.91]; p 0.02). No significant difference in primary events
as observed in the anticoagulant compared with the
ntiplatelet arm (HR 0.72 [95% CI 0.37 to 1.39], p 0.32).
he combined therapy arm had a lower rate of embolism-
able 1. Baseline Characteristics of the Study Participants
Interme
Triflusal
(n  242)
A
ge, yrs (SD) 69.9 (8)
o risk factors, age 60–74 yrs 16
en 57.0
urrent smokers 37.4
iabetes 17.1
yperlipidaemia 31.0
amily history of thrombotic disease 20.4*
ypertension 42.7
ean SBP, mm Hg (SD) 138 (17)
ean DBP, mm Hg (SD) 80 (11)
schemic heart disease 18.4
eripheral vascular disease 3.8
istory of heart failure 11.2
YHA functional class II to IV 59
V ejection fraction (SD) 61.0 (11)
A diameter, mm (SD) 46.2 (8)
ersistent/permanent atrial fibrillation 89.9
ioprosthesis† 2.2
onvalvular AF  prior embolism (n) —
itral stenosis  prior embolism (n) —
itral stenosis no prior embolism (n) —
ata expressed in percentage, unless otherwise indicated. *p  0.05 compared with
roup; if mitral valve area is narrower than 2 cm2 they are included in the high-risk
DBP  diastolic blood pressure; LA  left atrium; LV  left ventricle; NYHA
able 2. Anticoagulation Values in Different Therapeutic Groups
Intermediate
Anticoagulant
umber of INR controls 6,813
reset INR range 2.00–3.00
ean anticoagulant dose in mg (SD) 2.04 (0.80)
edian INR 2.47
(IQR: P25–P75) (2.33–2.60)
ime within range, % (SD) 65 (22)
ime over range, % (SD) 16 (17)
ime below range, % (SD) 19 (18)
ean inter-controls interval, days 26.50
umber INRs 2, % 21
umber INRs 3.5, % 6.30p  0.001 compared with the anticoagulant arm.
INR  international normalized ratio.troke-TIA than the antiplatelet arm (HR 0.21 [95% CI
.06 to 0.74]; p  0.01) and lower vascular death rate than
he anticoagulant arm (0.37 vs. 1.98, p  0.01). It also
howed a 61% relative reduction in outcome plus severe
leeding compared with either the antiplatelet (HR 0.39
95% CI 0.17 to 0.87], p  0.02) or the anticoagulant (HR
.38 [95% CI 0.17 to 0.87]; p  0.02) arms. The “on-
reatment” primary outcome rates were 2.95, 2.34, and 0.55
n the antiplatelet, anticoagulant, and combined therapy
rms, respectively, with a significant benefit in the combined
herapy when compared with either the antiplatelet (p 
.002) or the anticoagulant arms (p  0.005).
There were 43 primary events in the high-risk group.
able 3 shows their distribution and Figures 2B and 3 show
he primary event-free survival curves and the HR. The
-Risk Group High-Risk Group
gulant
237)
Combined
(n  235)
Anticoagulant
(n  259)
Combined
(n  236)
(7) 69.8 (7) 66.6 (9) 67.3 (10)
17 — —
.6 57.4 31.3 28.7
.0 40.2 28.3 22.4
.0 14.6 14.3 16.7
.0 27.4 30.4 32.4
.1 29.0 27.7 30.4
.0 45.2 33.2 30.0
(18) 136 (17) 136 (19) 134 (18)
(11) 79 (10) 77 (10) 77 (10)
.5 13.5 7.8 9.5
.7 2.7 3.3 1.8
.7* 10.5 20.6 14.1
44 44 45
(12) 60.0 (10) 63.7 (10) 62.1 (10)
(8) 47.0 (8) 52.6 (9) 51.7 (10)
.6 93.3 92.2 89.2
.8 2.2 2.3 3.3
— 95 89
— 50 45
— 114 102
er two groups. †Bioprosthesis normal functioning are included in intermediate-risk
.
w York Heart Association; SBP  systolic blood pressure.
Group High-Risk Group
Combined Anticoagulant Combined
5,478 7,421 5,833
1.25–2.00 2.00–3.00 1.40–2.40
1.61 (0.70)* 2.04 (0.80) 1.63 (0.70)*
1.93* 2.50 2.17*
(1.83–2.09) (2.37–2.65) (1.97–2.36)
66 (25) 67 (22) 73 (22)
31 (25) 15 (16) 23 (21)
3 (9) 18 (17) 4 (9)
27.20 27.50 28.00
67* 18 39*
1.96* 7.90 2.40*diate
nticoa
(n 
69.6
17
54
39
17
30
34
45
135
79
16
1
22
50
60.0
47.4
89
0
—
—
—
the oth-Risk
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October 19, 2004:1557–66 Antithrombotic Therapy in Atrial Fibrillationnticoagulant arm presented a primary outcome rate of 4.76
nd the combined therapy arm decreased this rate by 49%
HR 0.51 [95% CI 0.27 to 0.96]; p  0.03). The “on-
reatment” primary outcome rate difference was higher (1.1
s. 4.38) (p  0.001); eight additional primary or severe
leeding events occurred after withdrawal of the combined
herapy: four during anticoagulant and the other four during
ntiplatelet therapy alone.
The combined therapy, as compared with the anticoag-
lant therapy, decreased the aggregate embolism, stroke,
nd TIA rate by 56% in both the intermediate- and
igh-risk groups (Fig. 4A).
Figure 4B shows the embolism-stroke-TIA event-free
urvival curves throughout anticoagulant therapy in the
hree subgroups of the high-risk group and in nonvalvular
F patients without prior embolism. The survival curves
ere similar in nonvalvular and valvular patients either with
rior embolism at baseline (rates of 4.94 vs. 4.81, p  0.98)
r without embolism (1.43 vs. 1.26, p  0.57). However,
atients with mitral stenosis had a significantly lower
ncidence of several other risk factors: age (p  0.001),
iabetes (p  0.04), hypertension (p  0.01), and ischemic
eart disease (p 0.001). Patients with prior embolism had
significantly higher event rate than those without embo-
able 3. Number of Events in Each Treatment Group at Follow
Interm
Triflusal
(n  235)
A
atient-yrs 576.2
rimary outcome 22 (3.82)
rimary outcome (“OT”) 17
ascular death 8 (1.39)
Systemic embolism 0
Stroke 1
Bleeding 0
Sudden 5
Heart failure 2
HF due to avascular event 0
Myocardial infarction 0
onfatal stroke 10
IA 3
onfatal systemic embolism 1
onfatal MI 1
mbolism stroke and TIA 15 (2.60)
atal embolism-stroke-TIA 1 (0.17)
mbolism, stroke, AMI, and death from
vascular events
16 (2.78)
evere bleeding 2 (0.35)
Intracranial (intracerebral) 2 (2)
Gastric 0
Other 0
utcome  severe bleeding 22 (3.82)
onvascular death 7
onsevere bleeding 5
values of the combined therapy compared with the other arms: *p  0.05; †p  0
ailure due to repeated gastrointestinal bleeding.
AMI acute myocardial infarction; HF heart failure; MI myocardial infarctioism at baseline (p  0.006). tdverse events. We recorded a total of 42 severe bleeding
pisodes (Table 3): the antiplatelet arm in the intermediate-
isk group showed significantly fewer events than the antico-
gulant and the combined therapy arms. No difference was
ound between the anticoagulant and the combined therapy
rms. Fourteen bleeding events were intracranial (two in the
ntiplatelet arm, nine in the anticoagulant, and three in the
ombined arms). Fifteen hemorrhages were gastric, most of
hem in the combined therapy arms. By endoscopy, seven
atients in the combined therapy group showed superficial
ucosal erosions and three patients in the anticoagulant arm
howed recent ulcers.
ISCUSSION
he NASPEAF allows us to present, for the first time,
hree new aspects of antithrombotic treatment in AF. These
re the effect of anticoagulation alone versus combined
herapy with moderate anticoagulation, the event rate in
itral stenosis versus nonvalvular patients, and the event
ate in patients with prior embolism versus no embolism at
aseline.
In the intermediate-risk group, primary outcome was
ower with combined therapy than with the anticoagulant
e-Risk Group High-Risk Group
agulant
232)
Combined
(n  222)
Anticoagulant
(n  247)
Combined
(n  223)
6.1 540.8 609.7 573.1
2.70) 5 (0.92)* 29 (4.76) 14 (2.44) *
4 3† 26 6‡
1.98) 2 (0.37)† 17 (2.79) 6 (1.05)*
0 0 2 0
3 0 6 4
0 1 0 1
4 1 4 1
3 0 2 0
1§ 0 2 0
0 0 1 0
3 3 6 6
0 0 3 2
1 0 3 0
0 0 2 0
1.26) 3 (0.55) 20 (3.28) 12 (2.09)
0.54) 0 (0) 8 (1.31) 4 (0.70)
1.44) 4 (0.74) 25 (4.10) 13 (2.27)
1.80) 5 (0.92) 13 (2.13) 12 (2.09)
1) 1 (1) 5 (3) 2 (0)
1 3 3 8
5 1 5 2
3.78) 8 (1.48)* 34 (5.58) 22 (3.84)
9 4 6 6
5 16 18 20
p  0.001. §Heart failure due to repeated ischemic events. Two deaths from heart
T” on treatment; TIA transient ischemic attack; ( ) rate per 100 person-years-Up
ediat
ntico
(n 
55
15 (
1
11 (
7 (
3 (
8 (
10 (
4 (
21 (
1
.01; ‡herapy despite the anticoagulant maintaining a lower me-
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Antithrombotic Therapy in Atrial Fibrillation October 19, 2004:1557–66ian INR and three times as many INR controls 2.
rimary outcome plus severe bleeding was also lower with
he combined therapy, making this therapy the more effi-
acious and safer treatment.
In the high-risk group, the combined therapy showed a
ignificantly lower incidence of primary events when com-
ared with the anticoagulant therapy. This benefit was
btained with a lower median INR than in the anticoagu-
igure 2. Primary outcome Kaplan-Meier survival curves. (A) Intermedia
igh-risk group (mitral stenosis with/without embolism and nonvalvular a
rror.ant arm and with 39% of INR controls 2. Therefore, an aNR of 2, considered by the EAFT (16) and Hylek et al.
18) as the lower limit of safety during anticoagulant
herapy, is not applicable to patients receiving combined
herapy.
We planned a primary outcome, similar to that of the
AFT (16), composed of vascular death, systemic embo-
ism, and stroke. Primary outcome in other trials (7–9) was
he composite of systemic embolism and stroke. When we
group (nonvalvular atrial fibrillation without embolism at baseline). (B)
brillation with embolism at baseline). N  number at risk; SE  standardte-risk
trial finalyzed this outcome in the NASPEAF, the combined
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October 19, 2004:1557–66 Antithrombotic Therapy in Atrial Fibrillationherapy compared with the anticoagulant therapy decreased
he event rate of this aggregate by 56% in both the
ntermediate- and high-risk groups. Table 4 shows the
haracteristics and the embolism-stroke events rate in the
nticoagulant-alone and the combined therapy arms in the
ASPEAF and the three previous similar trials, but Ed-
ardsson et al. (9) did not include an anticoagulation therapy
rm. Our intermediate-group risk profile appears to be
imilar to that of the AFASAK II cohort (8) and our
igh-risk group appears to be similar to the SPAF III study
7). Although event rates with standard anticoagulation
ere similar, those with combined therapy in the
ntermediate- and high-risk groups in the NASPEAF
howed significant benefit compared with the AFASAK II
nd SPAF III study, respectively. The possible explanation
or this difference may be the higher anticoagulation inten-
ity achieved in the NASPEAF (median INR 1.93 to 2.17
n the intermediate- and high-risk groups) compared with
he other trials (median INR 1.3). The NASPEAF also
howed that efficacious combined therapy needs a moderate
nticoagulation intensity and that laboratory control is
andatory. Thus, INR levels 1.8 to 1.9 may not offer any
ignificant benefit and levels 2.5 are not needed.
Patients with prior embolism, investigated in published
rials, presented very high event rates with standard antico-
gulation. The composite of embolism-stroke-TIA was 3.9
n the EAFT (16), 4.6 in the SPAF III study high risk (7),
nd 4.8 in the NASPEAF. The corresponding rates of
ascular death were 4.1, 4.9, and 4.3 respectively, and severe
leeding was about 2 per 100 patients/year in the three
rials. The NASPEAF showed that combined antiplatelet
igure 3. Relative effect on vascular events of combined versus anticoagula
azard ratio whose 95% CI (error bars) excludes the vertical line are stati
yocardial infarction.nd moderate-intensity anticoagulation therapy could safely heduce the vascular event rate in this high-risk group of
atients.
Our trial also investigated antithrombotic treatment in
atients with AF plus mitral stenosis and in nonvalvular
atients. The embolic event rate, during equal anticoagulant
ntensity, was similar in either the valvular or nonvalvular
roups, without embolism (1.26 vs. 1.43) or with embolism
t baseline (4.81 vs. 4.94). The existence of valve stenosis
nd a predominant female gender in patients with mitral
tenosis were probably counterbalanced by an older age
nd a higher incidence of several other risk factors in
onvalvular patients. We have included mitral stenosis
atients without prior embolism in the high-risk group,
ut these patients presented a lower event rate than we
xpected and should probably be included in the
ntermediate-risk group.
Patients assigned to antiplatelet therapy presented a
elatively low event rate, consistent with other series of
atients with relative low intrinsic risk (19).
In the WARIS II (10), anticoagulation or combined
herapy were both superior to antiplatelet therapy alone in
ost-MI patients, but were not better or worse than each
ther. Here, combined therapy appeared to be superior to
ither anticoagulation or antiplatelet therapy alone in pa-
ients with AF; combined therapy could be indicated in
atients with both pathologies.
Anticoagulant therapy was controlled at anticoagulation
nits. The percentage of INR tests within the preset ranges
as 65 to 73, indicating a good control level (20). The
edian INR in the anticoagulant arms (target INR of 2 to
) was 2.47 in the intermediate-risk group and 2.50 in the
rapy. Log hazard ratio (HR) (95% confidence interval [CI])  logarithm
y significant at the 5% level (or significant with p  0.05). AMI  acutent theigh-risk group. The preset range in the combined arm of
t
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NR achieved was 1.93. The range in the combined arm of
he high-risk group was 1.4 to 2.4 and the median achieved
igure 4. Kaplan-Meier survival curves of the composite embolism-strok
urves in the combined therapy and anticoagulant arms of the intermedi
nticoagulant therapy for INR (2 to 3). ACO  anticoagulant; Emb/embolas 2.17; the achieved median INR in the combined arms tas greater than planned because our hematologists did not
ant low anticoagulation intensity and tended to maintain
he level of anticoagulation near the upper limit of the
sient ischemic attack (TIA) in different groups of patients. (A) Survival
nd high-risk groups. (B) Survival curves in groups of patients receiving
bolism; TIA  transient ischemic attack; other abbreviations as in Figure 2.e-tran
ate- aarget.
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ocation with standard anticoagulation, consisting with a
igher anticoagulation intensity (21). On the contrary,
astric bleeding was more common in the combined therapy
rms. The acid component of triflusal could be responsible
or the superficial erosions found by endoscopy, which lead
o bleeding when a certain level of anticoagulation is added.
Different trials (17,22–25) investigated combined therapy
n mechanic valve prosthetic patients. The incidence of
evere bleeding seems to be dose-related to either antiplate-
et or anticoagulant agent. Accordingly, there is a tendency
o use a low antiplatelet dose in the combined therapy. The
riflusal dose in our combined therapy arms was 600
g/day, which corresponded to aspirin 300 mg/day, and the
isk of nongastric severe bleeding was low. Two blind
ublished trials, Triflusal in Myocardial Infarction (TIM)
12) in post-MI patients and Triflusal versus Aspirin in
erebral Infarction Prevention (TACIP) (13) in post-
erebral infarction patients, compared triflusal 600 mg/day
o aspirin 300 to 325 mg/day. In both studies, no difference
n efficacy was found, but there was significantly higher
ajor hemorrhage or central nervous system hemorrhage
ith aspirin. Also, in the WARIS II (10) the combination
f aspirin 80 mg/day plus anticoagulation with an INR of
.2 offered higher risk of bleeding than anticoagulation
lone, for an INR of 2.8. Thus, although one can extrapo-
ate from the NASPEAF that the combination of antico-
gulation and aspirin is effective, a safe dose of aspirin
annot be determined, but the guidelines for valvular pros-
hesis (26) propose 75 to 100 mg/day in combined therapy.
The emerging benefit of direct antithrombin agents in
atients with AF (27), similar to anticoagulation for INR of
to 3, may influence future antithrombotic therapy in these
atients. However, an open question remains about the
fficacy of antithrombin agents in patients with previous
mbolism and those with mechanical valvular prosthesis, in
hom anticoagulation for an INR of 2 to 3 was not
ufficiently effective. We probably need new trials to evalu-
te the combination of antiplatelet and direct antithrombin
gents in these patients.
In conclusion, the addition of antiplatelet therapy to
able 4. Ischemic and Hemorrhagic Stroke and Systemic Emboli
Anticoagulant Therapy
n INR
Events
n Rate (Fatal)
PAF III (7) 523 2.4 14 2.4 (1.7)
FASAK II (8) 170 2.3 12 3.4 (0)
dvardsson et al. (9) placebo 6.5 (0.4)
ASPEAF: risk groups
Intermediate 232 2.5 7 1.3 (0.7)
High 247 2.5 20 3.3 (1.3)
n Edvardsson et al. (9), the control group was placebo and the level of INR in the com
as a risk profile similar to AFASAK II and the high-risk group is similar to SPAF
AFASAK Copenhagen Study on Atrial Fibrillation; ASA aspirin; Tri triflu
patient-years; SPAF  Stroke Prevention in Atrial Fibrillation.educed-intensity anticoagulation in AF patients stratifiedor risk of stroke significantly reduces subsequent events
ompared with patients receiving standard anticoagulation,
nd does so without increasing bleeding risk.
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